CAR T cells for solid tumors - developments to watch in 2023 [0.03%]
针对实体瘤的CAR-T细胞疗法——2023年值得关注的研究进展
Marcel P Trefny,Sebastian Kobold
Marcel P Trefny
Revolutionizing the management of patients with atopic dermatitis: practical considerations [0.03%]
特应性皮炎患者的管理：实际考虑因素
Filomena Russo,Anna Rita Giampetruzzi,Maria Antonietta Pilla et al.
Filomena Russo et al.
Equity, expense, and expertise in biologic commissioning: adding the patient to the equation [0.03%]
生物制剂委托中的权益、费用和专业技能：增加患者的变量因素
Seb Tucknott,Helen McAteer
Seb Tucknott
Introduction: Immune-mediated inflammatory diseases (IMIDs) are increasingly managed effectively with biologic medicines. However, with relatively high unit costs, there remains a meaningful pressure to ensure streamlined...
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting [0.03%]
双特异性抗体在成人急性白血病免疫治疗中的最新进展：来自美国血液学会第65届年会（2023）的更新报告
Lijie Han,Haizhou Xing,Weijie Cao et al.
Lijie Han et al.
Introduction Bispecific antibodies (BsAbs) represent a novel and potentially effective approach in cancer immunotherapy. These antibodies feature two unique binding domains, enabling them to simultaneously attach to two antigens or two epit...
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children [0.03%]
治疗儿童家族性高胆固醇血症的当前及新兴单克隆抗体疗法
M Doortje Reijman,D Meeike Kusters,Albert Wiegman
M Doortje Reijman
Introduction: Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder caused by pathogenic variants in the LDL-C metabolism. Lifelong exposure to elevated LDL-C levels leads to a high risk of premat...
The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients [0.03%]
omidubicel对脐带血移植患者免疫重建和感染的影响
Hong De Sa,Richard T Maziarz,Arpita P Gandhi
Hong De Sa
Introduction: The success of an allogeneic hematopoietic stem cell transplantation (alloHCT) is measured by cure from the underlying malignancy, immune reconstitution (IR), and freedom from graft-versus-host disease, with...
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden [0.03%]
对于高体重或疾病负担较高的中度至重度斑块型银屑病患者，使用Tildrakizumab进行个性化和灵活治疗的价值
Paolo Dapavo,Martina Burlando,Claudio Guarneri et al.
Paolo Dapavo et al.
Introduction: The introduction of biologics for the treatment of plaque psoriasis is one of the major therapeutic advances of the last decades in dermatology. The efficacy of this class of drugs can be influenced by multi...
Eloy E Ordaya,Raymund R Razonable
Eloy E Ordaya
Introduction: Anti-spike monoclonal antibodies (mAbs) were previously authorized for the prevention and treatment of COVID-19 in immunocompromised patients. However, they are no longer authorized in the U.S. due to their ...
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective [0.03%]
皮肤黑色素瘤的免疫疗法和银屑病的生物制剂治疗：临床多学科视角下的相似性和差异性
Gabriele Roccuzzo,Eleonora Gherardi,Michele Maio et al.
Gabriele Roccuzzo et al.
Introduction: Immunomodulating therapies harness the power of the immune system to combat disease. In advanced melanoma, immune checkpoint inhibitors have significantly improved survival outcomes by activating the immune ...
More failure with solanezumab - this time in preclinical Alzheimer's disease [0.03%]
solanezumab治疗preclinical阿尔茨海默病再次失败
Sheila A Doggrell
Sheila A Doggrell
Introduction: There is no cure for Alzheimer's disease, which is the sixth leading cause of death in the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer's disease but is only m...